Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Dotan, Efrat, Cohen, Steven J., Starodub, Alexander N., Lieu, Christopher H., Messersmith, Wells A., Simpson, Pamela S., Guarino, Michael J., Marshall, John L., Goldberg, Richard M., Hecht, J. Randolph, Wegener, William A., Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Berlin, Jordan D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8259133/
https://ncbi.nlm.nih.gov/pubmed/28817371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.9011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados